Hepatic Venoocclusive Disease with ImmunodeficiencySymptoms, Doctors, Treatments, Advances & More
Learn About Hepatic Venoocclusive Disease with Immunodeficiency
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
Paul Richardson is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is board certified in Medical Oncology.
Memorial Sloan Kettering Cancer Center
Nancy Kernan is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Kernan is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Hepatic Venoocclusive Disease with Immunodeficiency, Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Splenectomy.
Mohamad Mohty practices practicing medicine in Paris, France. Mr. Mohty is rated as an Elite expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.
Summary: This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses o...
Summary: This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.